Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Types, Stages Of Treatment, Patient Demographics, Treatment Settings, Duration Of Treatment, Drug Mechanism Of Action - Global Forecast 2025-2030- Product Image

Sale

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Types, Stages Of Treatment, Patient Demographics, Treatment Settings, Duration Of Treatment, Drug Mechanism Of Action - Global Forecast 2025-2030

Report
199 Pages
October 2024
Region: Global
360iResearch™
ID: 6011314

UP TO €665EUR$697USD£554GBP OFF until Dec 31^st 2024

The Chemotherapy Induced Peripheral Neuropathy Treatment Market grew from USD 905.35 million in 2023 to USD 974.24 million in 2024. It is expected to continue growing at a CAGR of 7.91%, reaching USD 1.54 billion by 2030.

Chemotherapy Induced Peripheral Neuropathy (CIPN) presents a significant field within the healthcare sector, focusing on addressing nerve damage caused by chemotherapy drugs. This condition often leads to debilitating symptoms such as pain and numbness, posing considerable challenges to patients' quality of life and their ability to continue effective cancer treatments. The necessity for CIPN treatments has generated a substantial demand for therapies that can either alleviate or prevent these symptoms, emphasizing a growing application scope across oncology clinics and hospitals. Moreover, the end-use scope extends to pharmaceutical and biotechnology companies actively engaged in the development of novel therapeutics and neurological research. Key growth influencers include increasing cancer prevalence, advancements in therapeutic technologies, and rising awareness of CIPN. Potential opportunities for market expansion lie in the development of non-invasive therapies, personalized medicine approaches, and interventions targeting neuro-inflammation. Companies can capitalize on these opportunities by investing in research collaborations with academic institutions and focusing on the unmet needs of cancer survivors. Challenges in the market consist of high R&D costs, regulatory hurdles, and limited understanding of the pathophysiology of CIPN, which hinder the acceleration of viable solutions into the marketplace. Furthermore, the variability of CIPN symptoms poses obstacles for standardized treatment protocols. To circumvent these limitations, investments in comprehensive clinical trials and advanced drug delivery systems are vital. Additionally, fostering partnerships with healthcare providers can facilitate more effective dissemination and adoption of emerging therapies. Innovators should prioritize exploring novel molecular targets and leveraging AI-driven research to forecast treatment outcomes. Overall, the CIPN treatment market demands robust innovation, where a strategic focus on personalized approaches and interdisciplinary research might provide significant competitive advantages. Successful navigation of this market involves striking a balance between scientific exploration, regulatory compliance, and patient-centric care solutions.

Understanding Market Dynamics in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Chemotherapy Induced Peripheral Neuropathy Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Expansion of healthcare infrastructure and access in developing regions
- Collaborations between pharmaceutical companies and research institutions for novel therapies
- Government initiatives and funding to support cancer treatment and neuropathy management
- Integration of telemedicine and digital health solutions in neuropathy treatment protocols
Market Restraints
- Challenges in clinical trial design for chemotherapy induced peripheral neuropathy treatments
- Regulatory hurdles in gaining approval for new chemotherapy induced peripheral neuropathy therapies
Market Opportunities
- Collaborating with pharmaceutical companies for breakthrough drug formulations targeting chemotherapy induced peripheral neuropathy
- Utilizing artificial intelligence and machine learning for personalized treatment plans in chemotherapy induced peripheral neuropathy
- Exploring dietary and lifestyle interventions to complement traditional chemotherapy induced peripheral neuropathy treatments
Market Challenges
- Navigating the complexities of combination treatments for chemotherapy-induced peripheral neuropathy
- Challenges in clinical trial design and patient recruitment in neuropathy treatment market

Exploring Porter’s Five Forces for the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Chemotherapy Induced Peripheral Neuropathy Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Chemotherapy Induced Peripheral Neuropathy Treatment Market

External macro-environmental factors deeply influence the performance of the Chemotherapy Induced Peripheral Neuropathy Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Chemotherapy Induced Peripheral Neuropathy Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Chemotherapy Induced Peripheral Neuropathy Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Chemotherapy Induced Peripheral Neuropathy Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Ipsen Pharma, Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Purdue Pharma L.P., Regenacy Pharmaceuticals LLC, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Peripheral Neuropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Types
- Non-Pharmacological Treatments
  - Acupuncture
  - Cognitive Behavioral Therapy
  - Occupational Therapy
  - Physical Therapy
  - Transcutaneous Electrical Nerve Stimulation (TENS)
- Pharmacological Treatments
  - Anticonvulsants
  - Antidepressants
  - Nutritional Supplements
  - Opioid Analgesics
  - Topical Agents
Stages Of Treatment
- Advanced Stage
- Initial Stage
- Mid Stage
Patient Demographics
- Age Group
  - Adult
  - Geriatric
  - Pediatric
- Gender
  - Female
  - Male
- Patient History
  - Genetic Factors
  - Pre-existing Conditions
  - Previous Chemotherapy Treatments
Treatment Settings
- Homecare
- Hospitals
- Specialty Clinics
Duration Of Treatment
- Long Term
- Short Term
Drug Mechanism Of Action
- Calcium Channel Modulators
- Gamma-Aminobutyric Acid (GABA) Analogues
- Opioids
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expansion of healthcare infrastructure and access in developing regions
5.1.1.2. Collaborations between pharmaceutical companies and research institutions for novel therapies
5.1.1.3. Government initiatives and funding to support cancer treatment and neuropathy management
5.1.1.4. Integration of telemedicine and digital health solutions in neuropathy treatment protocols
5.1.2. Restraints
5.1.2.1. Challenges in clinical trial design for chemotherapy induced peripheral neuropathy treatments
5.1.2.2. Regulatory hurdles in gaining approval for new chemotherapy induced peripheral neuropathy therapies
5.1.3. Opportunities
5.1.3.1. Collaborating with pharmaceutical companies for breakthrough drug formulations targeting chemotherapy induced peripheral neuropathy
5.1.3.2. Utilizing artificial intelligence and machine learning for personalized treatment plans in chemotherapy induced peripheral neuropathy
5.1.3.3. Exploring dietary and lifestyle interventions to complement traditional chemotherapy induced peripheral neuropathy treatments
5.1.4. Challenges
5.1.4.1. Navigating the complexities of combination treatments for chemotherapy-induced peripheral neuropathy
5.1.4.2. Challenges in clinical trial design and patient recruitment in neuropathy treatment market
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Types

6.1. Introduction
6.2. Non-Pharmacological Treatments
6.2.1. Acupuncture
6.2.2. Cognitive Behavioral Therapy
6.2.3. Occupational Therapy
6.2.4. Physical Therapy
6.2.5. Transcutaneous Electrical Nerve Stimulation (TENS)
6.3. Pharmacological Treatments
6.3.1. Anticonvulsants
6.3.2. Antidepressants
6.3.3. Nutritional Supplements
6.3.4. Opioid Analgesics
6.3.5. Topical Agents

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Stages Of Treatment

7.1. Introduction
7.2. Advanced Stage
7.3. Initial Stage
7.4. Mid Stage

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Demographics

8.1. Introduction
8.2. Age Group
8.2.1. Adult
8.2.2. Geriatric
8.2.3. Pediatric
8.3. Gender
8.3.1. Female
8.3.2. Male
8.4. Patient History
8.4.1. Genetic Factors
8.4.2. Pre-existing Conditions
8.4.3. Previous Chemotherapy Treatments

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Settings

9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Duration Of Treatment

10.1. Introduction
10.2. Long Term
10.3. Short Term

11. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Drug Mechanism Of Action

11.1. Introduction
11.2. Calcium Channel Modulators
11.3. Gamma-Aminobutyric Acid (GABA) Analogues
11.4. Opioids
11.5. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

12. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation

LIST OF FIGURES

FIGURE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2023 VS 2030 (%)
FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INITIAL STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY MID STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENETIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PRE-EXISTING CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PREVIOUS CHEMOTHERAPY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY CALCIUM CHANNEL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GAMMA-AMINOBUTYRIC ACID (GABA) ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS), BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 88. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 89. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 90. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 94. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 95. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 96. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 144. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 145. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 146. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 147. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 149. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 151. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 152. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 153. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 154. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 155. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 156. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 157. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 158. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 160. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 162. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 163. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 164. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 177. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 178. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 180. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 184. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 185. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 186. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 187. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
TABLE 244. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 245. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 246. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILL

Companies Mentioned

The leading players in the Chemotherapy Induced Peripheral Neuropathy Treatment market, which are profiled in this report, include:

AbbVie Inc.
Asahi Kasei Corporation
Astellas Pharma Inc.
AstraZeneca PLC
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Ipsen Pharma
Johnson & Johnson
Kyowa Kirin Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Purdue Pharma L.P.
Regenacy Pharmaceuticals LLC
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Incorporated

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	199
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 974.24 Million
Forecasted Market Value ( USD ) by 2030	$ 1540 Million
Compound Annual Growth Rate	7.9%
Regions Covered	Global
No. of Companies Mentioned	20

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3385EUR$3,545USD£2,818GBP €3761EUR$3,939USD£3,131GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€5989EUR$6,272USD£4,986GBP €6655EUR$6,969USD£5,539GBP

Understanding Market Dynamics in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Exploring Porter’s Five Forces for the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Applying PESTLE Analysis to the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Analyzing Market Share in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Strategic Recommendations for Success in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Chemotherapy-induced Peripheral Neuropathy - Market Insight, Epidemiology and Market Forecast - 2032

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034

Global Chemotherapy-Induced Peripheral Neuropathy Market, By Therapy, By Region, Estimation & Forecast, 2017 - 2030

Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024